Cargando…

Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018

BACKGROUND: Information about the specific regulatory environment of orphan drugs is scarce and inconsistent. Uncertainties surrounding the postmarketing long-term safety of orphan drugs remain. This study aimed to evaluate the labelling changes of orphan drugs and to identify postmarketing safety-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Min, Chan, Adrienne Y. L., Yan, Vincent K. C., Tong, Xinning, Lau, Lauren K. W., Wan, Eric Y. F., Tam, Eliza Y. T., Ip, Patrick, Lum, Terry Y., Wong, Ian C. K., Li, X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728968/ https://www.ncbi.nlm.nih.gov/pubmed/34983612 http://dx.doi.org/10.1186/s13023-021-02166-9

Ejemplares similares

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America
por: Arnold, Renée J.G., et al.
Publicado: (2015)

Clinical pharmacology information in regulatory submissions and labeling: A comparative analysis of orphan and non‐orphan drugs approved by the FDA
por: Hsieh, Julie, et al.
Publicado: (2022)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
por: Wallach, Joshua D., et al.
Publicado: (2019)

An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
por: Misu, Takashi, et al.
Publicado: (2018)

Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union
por: Żelewski, Paweł, et al.
Publicado: (2022)

Postmarketing all-case surveillance trends and contribution to safety measures of drugs approved in Japan: a cross-sectional survey in 1999–2019
por: Nakao, Minami, et al.
Publicado: (2022)

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
por: Morrissey, Kari M., et al.
Publicado: (2019)

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997–2012
por: Herder, Matthew, et al.
Publicado: (2016)

The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
por: Schuller, Y., et al.
Publicado: (2015)

Editorial: Orphan GPCRs As Emerging Drug Targets
por: Fang, Ye, et al.
Publicado: (2015)

Postmarketing Safety Study Tool: A Web Based, Dynamic, and Interoperable System for Postmarketing Drug Surveillance Studies
por: Sinaci, A. Anil, et al.
Publicado: (2015)

Trends in Cardiovascular Risk in the United States 1999 - 2018
por: Li, Hang Long, et al.
Publicado: (2021)

Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)

Association of smoking and osteoarthritis in US (NHANES 1999–2018)
por: Zhu, Senbo, et al.
Publicado: (2023)

Prevalence and trends of polypharmacy in U.S. adults, 1999–2018
por: Wang, Xiaowen, et al.
Publicado: (2023)

Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases
por: Schuller, Y., et al.
Publicado: (2017)

Compassionate use of orphan drugs
por: Hyry, Hanna I., et al.
Publicado: (2015)

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
Publicado: (2018)

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
por: Zhu, Xingyue, et al.
Publicado: (2022)

Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada
por: Gibson, Shannon, et al.
Publicado: (2015)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)

Estimating the impact of drug use on US mortality, 1999-2016
por: Glei, Dana A., et al.
Publicado: (2020)

Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act
por: Mechler, Konstantin, et al.
Publicado: (2015)

Prescription Patterns of Anti-dementia and Psychotropic Drugs in People Living With Dementia in China
por: Yingyang, Zhang, et al.
Publicado: (2021)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
por: Jarosławski, Szymon, et al.
Publicado: (2018)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

Mechanism of coordinated access to orphan drugs
por: DeRidder, R, et al.
Publicado: (2012)

Sex differences in chronic kidney disease awareness among US adults, 1999 to 2018
por: Hödlmoser, Sebastian, et al.
Publicado: (2020)

Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
por: Gammie, Todd, et al.
Publicado: (2015)

Predictors of orphan drug approval
por: Heemstra, Harald
Publicado: (2010)

Orphan drugs: Indian perspective
por: Kumar, Harish, et al.
Publicado: (2017)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

Trends in Blood Pressure and Hypertension Among US Children and Adolescents, 1999-2018
por: Hardy, Shakia T., et al.
Publicado: (2021)

The drug development pipeline for glioblastoma—A cross sectional assessment of the FDA Orphan Drug Product designation database
por: Johann, Pascal, et al.
Publicado: (2021)

Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018
por: Hansen, Chelsea L., et al.
Publicado: (2022)

Novel orphan medicines and abandoned pathways - the US Orphan Drug Act of 1983 and the impact on rare rheumatologic diseases and lysosomal storage disorders
por: Ries, Markus, et al.
Publicado: (2015)

Molecular Epidemiology and Trends in HIV-1 Transmitted Drug Resistance in Mozambique 1999–2018
por: Ismael, Nalia, et al.
Publicado: (2022)

Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval
por: Matsushita, Shunsuke, et al.
Publicado: (2021)

Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan
por: Kondo, Hideyuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i1q2kjabop1annqprqjpmsk2pb